Advertisement
U.S. Markets open in 7 hrs 35 mins
S&P Futures
6,003.25 -0.50 (-0.01%) Dow Futures
43,894.00 -16.00 (-0.04%) Nasdaq Futures
21,226.75 +2.00 (+0.01%) Russell 2000 Futures
2,395.50 -0.20 (-0.01%) Crude Oil
71.73 -0.63 (-0.87%) Gold
2,694.30 -11.50 (-0.43%)
ImmunityBio, Inc. (IBRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 5.42 |
| Open | 5.39 |
| Bid | 5.27 x 1000 |
| Ask | 5.33 x 1100 |
| Day's Range | 5.19 - 5.60 |
| 52 Week Range | 2.66 - 10.53 |
| Volume | |
| Avg. Volume | 4,854,914 |
| Market Cap | 3.692B |
| Beta (5Y Monthly) | -0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
- GuruFocus.com
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
Game-Changing Cancer Therapy Trial Ignites Investor Frenzy--Will ImmunityBio Hit $30 Soon?
Business WireFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
CULVER CITY, Calif., October 24, 2024--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are being tested initially as a single agent, and after demonstrating safety, then in combination with standard NHL tre
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.